HUMANIGEN, INC: Nasdaq/NYSE listing notice — Humanigen receives additional Nasdaq delisting notice for MVLS non-compliance; hearing held April 6

HUMANIGEN, INC

Nasdaq notified Humanigen on April 5 that it failed to meet minimum $35M MVLS requirement as of April 3.
Company requested a 180-day extension until Aug 21, 2023 at hearing on April 6; Panel decision expected within 30 days.
Trading suspension stayed pending hearing process and any extension granted, up to 180 days from Feb 21, 2023.
Non-compliance also involves bid price below $1.00 and stockholders' equity requirements for Nasdaq Capital Market.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

HUMANIGEN, INC received a nasdaq delisting notice notice regarding market value.

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value

Exact text from the filing

April 5, 2023, prior to the Hearing, the Company received a letter from the Nasdaq Staff notifying the Company that it had not regained compliance with the minimum MVLS requirement as of April 3, 2023 and that this deficiency would serve as an additional basis for delisting the Company’s securities from Nasdaq. The Nasdaq Staff’s letter also informed the Company that the Panel would consider, and the Company should address, this additional deficiency at the Hearing. At the Hearing held before the Panel on April 6, 2023, the Company outlined its plans for regaining compliance with the minimum b

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001214659-23-005046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.